(Cilnidipine + tadalafil) is under clinical development by AISA Pharma and currently in Phase II for Raynauds Disease. According to GlobalData, Phase II drugs for Raynauds Disease have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Cilnidipine + tadalafil)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cilnidipine + tadalafil) overview
Profervia is under development for the treatment of Raynaud's disease and digital ulcerations in scleroderma patients, neuropathic pain, complex regional pain syndrome and Systemic Sclerosis (Scleroderma). It is a fixed-dose combination of cilnidipine and tadalafil, the combination is administered through oral route in the form of tablet. Tadalafil acts by targeting cGMP specific phosphodiesterase (PDE5) and cilnidipine acts by targeting voltage dependent L and N type calcium channels.
AISA Pharma overview
AISA Pharma is a healthcare provider which provides treatments to patients with rare serious diseases in the fields of vasculature, heart, kidney, and nervous system with the help of clinical trials. AISA Pharma is headquartered in Boston, Massachusetts, the US.
For a complete picture of (Cilnidipine + tadalafil)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
